Ann: Pharmaxis Completes Recruitment of CF Clinical Trial for US-PXS.AX, page-9

I've held for about 7 years. At conferences such as Ausbiotech I have watched the discourse around PXS go from pinup boy to fallen angel and now a subtle interest that not many wish to discuss. (and I think this reticence is due to purchase) I bought some more last week because the betting seems to be pointing to going upwards rather than backwards. I am way down the pecking order with insight as to the true value of what they have, how they can stitch up deals and whether or not they can navigate through it all and end up with something the FDA gives a thumbs up to - but the feeling I get from the smarties within the industry is PXS has re-risen admirably and is a whipping boy no more. To me, a healthy risk- but talk is cheap. Probably know by this time next year.